Formycon
Logotype for Formycon AG

Formycon (FYB) investor relations material

Formycon Q3 2026 earnings summary

Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Logotype for Formycon AG
Q3 2026 earnings summary12 Nov, 2026

Executive summary

  • Nine-month revenue doubled to €40.0m from €19.5m; reported EBITDA loss narrowed to €8.9m from €21.4m.

  • FYB201 and FYB202 market deterioration led to substantial non-cash impairments, expected to reduce 2026 net result by ~€121m.

  • FYB206’s BLA was accepted for FDA review, while FYB286 launched as a partner-funded co-development program.

Financial highlights

  • Nine-month revenue was €40.0m, including €20.7m milestone revenue, €9.7m royalties, €7.6m development-service recharges and €2.0m supply-management services.

  • Reported EBITDA improved to -€8.9m from -€21.4m; adjusted EBITDA, including Bioeq AG’s at-equity result, improved to -€14.9m from -€21.7m.

  • Cost of sales rose to €47.9m from €37.3m, including FYB206 development work and scheduled FYB202 amortization; R&D expense fell to €3.8m from €9.5m.

  • Capitalized development expenditure for FYB206 and FYB208 fell to €16.2m from €31.9m, mainly following completion of FYB206 clinical work and its PK study.

Outlook and guidance

  • FY2026 revenue guidance remains €60m–€70m and reported EBITDA €0m–€10m, both expected at the lower end; working-capital guidance remains €20m–€30m.

  • Adjusted EBITDA guidance was revised to -€15m to -€5m from €5m–€15m, reflecting weaker Bioeq AG earnings and reduced FYB201 expectations.

  • Q4 contributions are expected from FYB206 deferred revenue, partnerships, portfolio commercialization and development activity; recognition timing affects guidance.

  • FYB206’s FDA decision could come in Q3 2027; LATAM partnership revenue is included in 2026 guidance, with further partnerships and territory milestones possible in 2027.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
Research faster. Power your platform.

Next Formycon earnings date

Logotype for Formycon AG
Q4 202625 Mar, 2027
Formycon
Cover every name on your watchlist this earnings season.
Automations, AI chat, and live calls across 16,000+ companies.
Book demo

Next Formycon earnings date

Logotype for Formycon AG
Q4 202625 Mar, 2027

AI chat

Ask anything. Verify everything.

Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn more

Automations

Zero in on what matters

Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more

Live audio & transcripts

Be first

Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more

Quartr MCP connects your AI environment to 17K+ public companies

Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more

Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.

Jamie Ross

Investment Manager, GAM Investments

GAM
GAM

Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.

Tom O'Hara

Investment Director

Ciena
Ciena

Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.

Gregg Lampf

VP of Investor Relations

Frequently asked questions

Formycon AG is a German biotechnology company specializing in the development of biosimilars, which are biologic medical products highly similar to approved reference drugs. The company's portfolio includes biosimilars for treatments in areas such as ophthalmology and immunology, targeting chronic diseases with a high demand for cost-effective therapies. Formycon is involved in all stages of biosimilar development, from research and production to clinical trials and regulatory approval, aiming to expand access to high-quality biologics in global markets.The company is headquartered in Planegg, Germany, and its shares are listed on the Frankfurt Stock Exchange.